SCHEMBL1397495

SCHEMBL1397495

CC(=O)N1CCN(c2ccc(C(N)=O)cc2C(F)(F)F)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C19 P33261 1/20 0.52
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HSD11B1 P28845 4/20 0.48
ADRA1D P25100 1/20 0.48
HTR2A P28223 1/20 0.48
SLC6A3 Q01959 1/20 0.48
SLC9A2 Q9UBY0 1/20 0.48
NPY2R P49146 1/20 0.47
PIK3CA P42336 1/20 0.45
MTOR P42345 1/20 0.45
PIK3CG P48736 1/20 0.45
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
TTR P02766 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16380654 0.86 KDM4E (0.66) SLC9A1CYP3A4CYP2C19KDM4EALDH1A1
SCHEMBL1397423 0.85 ALDH1A1 (0.55) SLC9A1CYP3A4CYP2C19KDM4EALDH1A1
SCHEMBL264195 0.84 GFER (0.54) SLC9A1CYP3A4CYP2C19KDM4EALDH1A1
SCHEMBL31316983 0.84 GFER (0.54) SLC9A1CYP3A4CYP2C19KDM4EALDH1A1
SCHEMBL16380652 0.83 CHRM1 (0.48) SLC9A1CYP3A4CYP2C19KDM4EALDH1A1
SCHEMBL8261930 0.83 CTPS1 (0.62) SLC9A1KDM4EALDH1A1HSD17B10HSD11B1
SCHEMBL3099613 0.82 ALDH1A1 (0.57) KDM4EALDH1A1HSD17B10
SCHEMBL10259980 0.82 ALDH1A1 (0.48) ALDH1A1NPY2R
SCHEMBL2709426 0.81 SMN1; SMN2 (0.56) SLC9A1CYP3A4CYP2C19KDM4EALDH1A1
SCHEMBL22914786 0.81 ENPP2 (0.46) SLC9A1CYP3A4CYP2C19ALDH1A1NPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190834-B1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2011-03-02 EP claimed
EP-2190834-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. Hoffmann-Roche AG (CH) 2010-06-02 EP claimed
EP-2065380-A1 Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer F.HOFFMANN-LA ROCHE AG (CH) 2009-06-03 EP claimed
WO-2009024332-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-02-26 WO claimed
EP-2190834-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. Hoffmann-Roche AG (CH) 2010-06-02 EP disclosed
EP-2065380-A1 Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer F.HOFFMANN-LA ROCHE AG (CH) 2009-06-03 EP disclosed
WO-2009024332-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-02-26 WO disclosed